Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
CTI Life Sciences Fund is a Canadian venture capital firm founded over 20 years ago, focusing on the biotechnology sector. The firm manages a diverse portfolio of 12 companies and emphasizes both long-term value creation and expedited exit timelines.
CTI Life Sciences Fund invests in therapeutic and modality-agnostic biotech companies at various stages, including pre-seed through Series C. The firm seeks to support the development of scalable and marketable biotech solutions, aiming for both innovation and rapid market entry.
Notable portfolio companies include Ability Pharma, developing a treatment for metastatic pancreatic cancer; Aeovian Pharmaceuticals, focused on mTORC1-specific inhibitors; and DalCor, which originated from a precision cardiology asset. Other companies include enGene, Epitopea, Find Therapeutics, Glycomine, Kainova Therapeutics, Oligon Therapeutics, Phenomic AI, Profound, and Thryv Therapeutics.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.